Wednesday, August 28, 2019 11:16:55 AM
I agree. That guy/girl sounds like he/she has no idea what they’re talking about and any and all statements must be purely fictional. It’s just uncanny how accurate they’ve been.
There’s another simple explanation for why the company hasn’t been able to progress as quickly as they’ve stated, but seems to be difficult for some to acknowledge as even a slight possibility.
Isn’t it possible that this endeavor was set up to enrich those who hatched it? $98M is a pretty nice piece of change for 15 years of work without having to actually deliver a single credible result.
Maybe?
I was wondering, if they haven’t produced at kg scale, and they go out of business, what is the realistic negative impact for their “misleading” statements?
There’s another simple explanation for why the company hasn’t been able to progress as quickly as they’ve stated, but seems to be difficult for some to acknowledge as even a slight possibility.
Isn’t it possible that this endeavor was set up to enrich those who hatched it? $98M is a pretty nice piece of change for 15 years of work without having to actually deliver a single credible result.
Maybe?
I was wondering, if they haven’t produced at kg scale, and they go out of business, what is the realistic negative impact for their “misleading” statements?
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
